TIDMAPH

Alliance Pharma PLC

11 January 2018

Hardman Research: Acquisitions to boost growth prospects

Acquisitions to boost growth prospects - Alliance Pharma is continuing with its buy-and-build strategy, having evolved through 35 acquisitions over a period of 20 years into a profitable, cash generative, specialty pharma business. The company has a mix of international growth brands - notably Kelo-cote and MacuShield - and a bedrock of solid local low-growth brands. APH is adding new products to each of these areas with the recent acquisitions of Ametop (bedrock) and Vamousse (international growth), both for cash from the company's existing Revolving Credit Facility, and, given the good margins, these are expected to be earnings accretive by the end of the first year of ownership.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/11.01.18-acquisitions-to-boost-growth-prospects.pdf

 
 To contact us:                        Contacts:          mh@hardmanandco.com 
  Hardman & Co                          Dr Martin Hall     dmh@hardmanandco.com 
  35 New Broad Street                   Dr Dorothea        gp@hardmanandco.com 
  London                                Hill               www.hardmanandco.com 
  EC2M 1NH                              Dr Gregoire 
  Follow us on Twitter @HardmanandCo    Pave 
                                        +44 20 7194 
                                        7622

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAKBLFFVFFLBBX

(END) Dow Jones Newswires

January 11, 2018 02:15 ET (07:15 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.